6 Athira Pharma LIFT-AD topline results (press release)September 3, 2024 announcement that fosgonimeton (a distinct HGF/c-Met modulator) did not meet the primary or key secondary endpoints in the Phase 2/3 LIFT-AD Alzheimers trial
Quick nationwide delivery
While less common, the most serious side effects of glutathione are described below, along with what to do if they happen
This infographic walks you through the effects of the Cbl, symptoms, inheritance pattern, how it's diagnosed, specialist included in treatment and what patients lives look like if treated early
Footnotes Contributors: TAS, IK, MH and RKC conceived the study, and contributed to study design, sample size calculations and analytical plans